Fructose metabolism (Homo sapiens)
From WikiPathways
Description
Fructose is found in fruits, is one of the components of the disaccharide sucrose, and is a widely used sweetener in processed foods. Dietary fructose is catabolized in the liver via fructose 1-phosphate to yield dihydroxyacetone phosphate and glyceraldehyde 3-phosphate, which then are converted to pyruvate via steps of canonical glycolysis (Hers & Kusaka 1953; Sillero et al. 1969). Excessive dietary intake of fructose and its metabolism have been associated with major disease risks in humans, although this issue remains controversial (Kolderup & Svihus 2015; DiNicolantonio et al. 2015; Bray 2013; Mayes 1993; Rippe & Angelopoulos 2013; van Buul et al. 2013). Fructose can also be synthesized from glucose via the polyol pathway (Hers 1960; Oates 2008). This synthetic process provides the fructose found in seminal fluid and, in other tissues, can contribute to pathologies of diabetes.
View original pathway at:Reactome.
Try the New WikiPathways
View approved pathways at the new wikipathways.org.Quality Tags
Ontology Terms
Bibliography
History
External references
DataNodes
Annotated Interactions
ALDOB is the same aldolase isoform that catalyzes the reversible cleavage of fructose-1,6-bisphosphate in glycolysis. This isoform, found in liver, kidney, and intestine, is approximately equally active with fructose 1 phosphate and fructose 1,6 bisphosphate as substrates at saturating concentrations, while the muscle and brain isoforms (ALDOA and ALDOC, respectively), have little activity with fructose-1-phosphate (Lebherz & Rutter 1969; Penhoet et el. 1969).
DAK/TKFC is a bifunctional enzyme which, besides the ATP/Mg-dependent phosphorylation of GA and DHA, also catalyses, in presence of Mn2+, a unisubstrate reaction splitting flavin-adenine dinucleotide (FAD) into riboflavin cyclic 4',5'-phosphate (cyclic FMN) and AMP (Cabezas et al. 2005; Rodrigues et al. 2014).
In addition, DAK/TKFC protein binds to MDA5 and acts as a negative regulator of MDA5-mediated induction of IFN-alpha/beta pathways (Diao et al. 2007). Potentially related to this TKFC effect are the observations that hepatic DAK/TKFC levels correlate with outcome in chronic hepatitis C patients treated with interferon (Perdomo et al. 2012), and that a DAK/TKFC serum peptide is a predictor of disease severity in hepatitis B patients (Xu et al. 2013).